NEW HAVEN, Conn. — Designed to tackle the most critical challenges in modern cancer treatment through multi-disciplinary collaboration, the inaugural Future of Oncology Summit is set to bring together approximately 400 attendees and over 70 speakers at 101 College Street in New Haven.
Co-hosted by the Yale Cancer Center (YCC) and BioCT, the core goal of the two-day summit is to merge discovery, technology, capital, and clinical translation so that breakthrough cancer innovations can move swiftly into real-world progress.
Summit Overview and Focus Areas
Oncology stands at a genuine turning point, requiring diverse sectors to unite under a shared mission. To foster forward-looking insights, the program is centered around three interconnected pillars:
-
Innovation: Focusing on fundamental tumor biology, precision medicine, and translating scientific breakthroughs into enhanced patient care.
-
Intelligence: Exploring the expanding role of artificial intelligence (AI) and data platforms across the entire cancer continuum—from early detection and drug discovery to clinical trial design.
-
Investment: Highlighting business development, venture capital, and strategic partnerships required to scale promising concepts.
Collaborative Leadership and Key Perspectives
The summit reflects a powerful partnership between YCC’s clinical and research expertise and BioCT’s network linking Connecticut’s life sciences community.
-
Dr. Eric Winer (Director of YCC and president and physician-in-chief of Smilow Cancer Hospital), who co-chairs the event alongside BioCT board co-chair David Scheer, emphasized that no single discipline can master this transformation alone.
-
David Scheer (President of Scheer & Company, Inc.) noted that the gathering is intended to put scientists, technologists, clinicians, and investors in the same room to turn a golden age of science into tangible patient outcomes.
-
Keynote speaker Clifford Hudis, MD (CEO of the American Society of Clinical Oncology) underscored that leveraging AI and data platforms appropriately will expand healthcare access and empower clinicians to focus on patients.
-
Investor perspective keynote Annie Lamont (Co-founder and managing partner of Oak HC/FT) pointed out that the proliferation of AI and a new wave of entrepreneurs make this an ideal environment to back life-changing treatments.
-
Jodie Gillon (President and CEO of BioCT) highlighted that the high-profile participation—underscored by local success stories like Halda Therapeutics—proves New Haven has emerged as a premier global center for research and development.